Dr. Hope’s main research focus is on novel imaging agents and therapies, particularly in prostate cancer and neuroendocrine tumors. He lead the development of Ga-68 PSMA-11, which subsequently led to the approval of this drug by the FDA. He has combined his interest in MR imaging with PET in the simultaneous modality PET/MRI, helping lead the development of the clinical PET/MRI program. Additionally he leads the PRRT (peptide receptor radionuclide therapy) program for neuroendocrine tumors and PSMA Radioligand Therapy at UCSF.
An international leader in PET/MR research and the translation of new molecular imaging agents, Dr. Hope launched the highly successful PSMA prostate program at UCSF and championed the use of multiple new targeted therapies to treat patients with neuroendocrine and other tumors. He current serves as principal investigator on grants from the NIH, the Prostate Cancer Foundation. He is the recipient of numerous accolades in molecular imaging, including the Henkin Fellow and Marc Tetalman Memorial Award from the Society of Nuclear Medicine and Molecular Imaging, the Young Investigator Award from the Prostate Cancer Foundation and the Wylie J. Dodds Research Award from the Society of Abdominal Radiology.